

---

## Press Release

---

May 22, 2026

Sumitomo Pharma Co., Ltd.

### **Notice Regarding Results of Capital Increase by way of Third-Party Allotment (Not Implemented)**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE; the “Company”) announced that, with respect to the issuance of new shares by way of third-party allotment, which was resolved together with the issuance of new shares by way of public offering (Public Offering) and the secondary offering of shares (Offering by way of Over-allotment) at the Board of Directors’ meeting held on April 8, 2026, SMBC Nikko Securities Inc., which is the allottee, notified the Company that it will not subscribe for any of the shares scheduled to be issued by the end of the subscription date (May 25, 2026).

Accordingly, all of the 7,695,600 shares initially scheduled to be issued will not be issued, and the Company hereby announces that the issuance of new shares by way of third-party allotment will not be implemented.

End.

Contact:

Corporate Communications,

Sumitomo Pharma Co., Ltd.

E-mail: [prir@sumitomo-pharma.co.jp](mailto:prir@sumitomo-pharma.co.jp)

<p>Note: This press release is a general release regarding the results of capital increase by way of third-party allotment, and is not prepared for the purpose of investment solicitation or the like in Japan or elsewhere. This press release does not constitute an offer to sell or solicitation of any offer to buy securities in the United States. The shares of common stock of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”). The shares of common stock of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the shares of common stock of the Company will take place in the United States.</p>
--